Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2010-1-21
pubmed:abstractText
Renal cell carcinomas (RCC) are refractory to standard therapy with advanced RCC having a poor prognosis; consequently treatment of advanced RCC represents an unmet clinical need. The von Hippel-Lindau (VHL) tumor suppressor gene is mutated or inactivated in a majority of RCCs. We recently identified a 4-pyridyl-2-anilinothiazole (PAT) with selective cytotoxicity against VHL-deficient renal cells mediated by induction of autophagy and increased acidification of autolysosomes. We report exploration of structure-activity relationships (SAR) around this PAT lead. Analogues with substituents on each of the three rings, and various linkers between rings, were synthesized and tested in vitro using paired RCC4 cell lines. A contour map describing the relative spatial contributions of different chemical features to potency illustrates a region, adjacent to the pyridyl ring, with potential for further development. Examples probing this domain validated this approach and may provide the opportunity to develop this novel chemotype as a targeted approach to the treatment of RCC.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-10235157, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-10353251, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-10561319, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-11574546, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-12510195, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-12583731, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-12912922, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-13679920, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-14712081, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-15205579, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-15611513, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-16110319, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-16642001, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-17575159, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-18598947, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-19474385, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-7915601, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-8855222, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-8855223, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-9443397, http://linkedlifedata.com/resource/pubmed/commentcorrection/19994864-9651579
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1520-4804
pubmed:author
pubmed:issnType
Electronic
pubmed:day
28
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
787-97
pubmed:dateRevised
2011-7-20
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death.
pubmed:affiliation
Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand. m.hay@auckland.ac.nz
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural